We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

163 hedge funds and large institutions have $1.48B invested in Celldex Therapeutics in 2014 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 63 increasing their positions, 36 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 18

75% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 36

44% more capital invested

Capital invested by funds: $1.03B → $1.48B (+$450M)

10% more funds holding

Funds holding: 148 → 163 (+15)

48% less call options, than puts

Call options by funds: $19.3M | Put options by funds: $36.9M

Holders
163
Holders Change
+15
Holders Change %
+10.14%
% of All Funds
4.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
36
Increased
63
Reduced
36
Closed
18
Calls
$19.3M
Puts
$36.9M
Net Calls
-$17.6M
Net Calls Change
-$16.2M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$22.8M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$18.3M
3
VOYA Investment Management
VOYA Investment Management
Georgia
+$10.3M
4
CCI
Columbus Circle Investors
+$8.66M
5
O
OppenheimerFunds
New York
+$7.95M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$39.2M
2
Franklin Resources
Franklin Resources
California
-$10.9M
3
AAP
Ardsley Advisory Partners
Connecticut
-$7.32M
4
TCM
Tekla Capital Management
Massachusetts
-$6.59M
5
CWAM
Columbia Wanger Asset Management
Illinois
-$6.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
HM
51
HealthCor Management
New York
$2.99M +$2.71M +10,907 New
D.E. Shaw & Co
52
D.E. Shaw & Co
New York
$2.88M +$936K +3,763 +56%
FLAM
53
First Light Asset Management
Minnesota
$2.8M +$179K +720 +8%
New York State Common Retirement Fund
54
New York State Common Retirement Fund
New York
$2.79M +$401K +1,613 +19%
Citadel Advisors
55
Citadel Advisors
Florida
$2.71M -$247K -992 -9%
CS
56
Candriam SCA
Luxembourg
$2.56M +$2.32M +9,333 New
Prudential Financial
57
Prudential Financial
New Jersey
$2.18M -$38K -153 -2%
EI
58
EAM Investors
California
$2.06M +$1.87M +7,505 New
ACM
59
Apex Capital Management
Ohio
$1.97M +$1.79M +7,213 New
Bank of America
60
Bank of America
North Carolina
$1.95M +$47.7K +192 +3%
NFA
61
Nationwide Fund Advisors
Ohio
$1.95M +$89K +358 +5%
SIA
62
Sit Investment Associates
Minnesota
$1.91M -$133K -536 -7%
IHM
63
Iguana Healthcare Management
New York
$1.82M -$829K -3,333 -33%
NSEDCP
64
NJ State Employees Deferred Compensation Plan
New Jersey
$1.82M – – –
PA
65
Perceptive Advisors
New York
$1.82M +$1.66M +6,667 New
Swiss National Bank
66
Swiss National Bank
Switzerland
$1.8M +$38K +153 +2%
RhumbLine Advisers
67
RhumbLine Advisers
Massachusetts
$1.63M +$93.7K +377 +7%
Ameriprise
68
Ameriprise
Minnesota
$1.56M +$640K +2,576 +83%
American Century Companies
69
American Century Companies
Missouri
$1.52M -$2.24K -9 -0.2%
NI
70
Numeric Investors
Massachusetts
$1.44M +$1.31M +5,260 New
ProShare Advisors
71
ProShare Advisors
Maryland
$1.43M -$50.5K -203 -4%
Millennium Management
72
Millennium Management
New York
$1.43M +$1.12M +4,498 +625%
PAM
73
Paradigm Asset Management
New York
$1.4M +$1.27M +5,127 New
State Board of Administration of Florida Retirement System
74
State Board of Administration of Florida Retirement System
Florida
$1.36M +$9.7K +39 +0.8%
MLICM
75
Metropolitan Life Insurance Company (MetLife)
New York
$1.31M – – –
1 2
3
4 5

CLDX Hedge Fund Activity: Q4 2014 in Review

163 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2014, worth a combined $1.48B — up 44% from $1.03B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new CLDX positions and 18 closed out — a net gain of 18 holders — while 63 added to existing stakes and 36 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $22.8M. The largest seller was Jennison Associates, exiting entirely with an estimated $39.2M sold.

  • 163 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2014, up from 148 in Q3 2014.
  • Funds reported $1.48B of Celldex Therapeutics stock for Q4 2014, up 44% quarter-over-quarter.
  • 36 funds opened new Celldex Therapeutics positions in Q4 2014 and 18 closed out, a net change of +18 holders.
  • The largest Celldex Therapeutics buyer in Q4 2014 was Fidelity Investments, an estimated $22.8M added.
  • The largest Celldex Therapeutics seller in Q4 2014 was Jennison Associates, an estimated $39.2M sold.

Based on aggregated 13F filings for Q4 2014.